Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, Ma...
February 28 2019 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that it
will report fourth quarter and full year 2018 financial results and
provide a corporate update before market open on Wednesday, March
6, 2019. Jounce Therapeutics' management team will host a live
conference call and webcast at 8:00 a.m. ET.
Conference Call and WebcastTo access the
conference call, please dial (866) 916-3380 (domestic) or (210)
874-7772 (international) and refer to conference ID 8678456. The
live webcast can be accessed under "Events & Presentations" in
the Investors and Media section of the company's website at
www.jouncetx.com. The webcast will be archived and made available
for replay on the company’s website approximately two hours after
the call and will be available for 30 days thereafter.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within the
human tumor microenvironment to prioritize targets, and then
identifies related biomarkers designed to match the right
immunotherapy to the right patient. Jounce has three
development-stage programs: its two clinical product candidates,
JTX-2011, a monoclonal antibody that binds to and
activates ICOS, and JTX-4014, a monoclonal antibody that binds
to PD-1 and for potential use in combination with Jounce’s pipeline
of future product candidates, and JTX-8064, a monoclonal antibody
that binds to Leukocyte Immunoglobulin Like Receptor B2 (LILRB2)
that is currently in the IND-enabling phase. For more information,
please visit www.jouncetx.com.Investor
Contact:Komal JoshiJounce Therapeutics, Inc.(857)
320-2523kjoshi@jouncetx.com
Media Contact:Gina NugentThe Yates Network(617)
460-3579gina@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024